Opthea Limited (OPT)
| Previous close | 3.3900 |
| Open | 3.3900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.3800 - 3.5700 |
| 52-week range | 1.6000 - 4.4000 |
| Volume | |
| Avg. volume | 18,606 |
| Market cap | 283.184M |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.4100 |
| Earnings date | 28 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.95 |
GlobeNewswireOpthea Announces Upcoming Presentations at the Retina World Congress 2024
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that two scientific presentations on the sozinibercept (OPT-302) Phase 2 clinical trial results and ongoing Phase 3 clinical trial program will be made at the Retina World C
- GlobeNewswire
Opthea to Present at the OIS Retina Innovation Summit at ARVO
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company’s clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina
Simply Wall St.Owning 39% shares,institutional owners seem interested in Opthea Limited (ASX:OPT),
Key Insights Institutions' substantial holdings in Opthea implies that they have significant influence over the...
